A pilot study and a randomized-controlled trial alongside cost-effectiveness analysis of the comparative efficacy between cannabidiol (CBD)-containing ointment and 50 mcg/g calcipotriol ointment and 0.1% triamcinolone cream in the treatment of plaque-type psoriasis
- Conditions
- Mild plaque-type psoriasisMarijuana, Cannabis, Cannabidiol, Calcipotriol, Triamcinolone, Plaque-type psoriasis, Cost
- Registration Number
- TCTR20230117009
- Lead Sponsor
- Institute of dermatology, Ministry of public health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 60
1. Male or female diagnosed with mild plaque-type psoriasis
2. Age 18-60 years
3. Otherwise healthy
4. Willing to participate and can come for scheduled follow-ups
1. Have acute skin inflammation/infection which is not psoriasis
2. Have been treated with topical tar-containing products, vitamin A and vitamin D derivatives, corticosteroids, UVB phototherapy withinthe previous two weeks
3. Have been treated with oral vitamin A derivatives, corticosteroids, cyclosporine, methotrexate, PUVA phototherapy or laser therapy within the previous 4 weeks
4. Have been treated with immunosuppressants such as alefacept, etanercept, infliximab, efalizumab or adalimumab within the previous 12 weeks
5. Have other diseases or currently taking other drugs which may interfere with normal skin function and with this study such as beta-blocker, lithium, oral contraceptive pill, ACE inhibitor, antimalarial, NSAIDS, interferon, imiquimod, gemfibrozil
6. Have a history of allergy to cannabis/cannabis products, steroids, vitamin D derivatives
7. Pregnant of breast-feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy 2 months ESI/IGA score
- Secondary Outcome Measures
Name Time Method cost-effectiveness 2 month cost-effectiveness analysis